Benufutamab Biosimilar – Anti-TNFRSF10B, TRAILR2, CD262 mAb – Research Grade

Description of Benufutamab Biosimilar - Anti-TNFRSF10B, TRAILR2, CD262 mAb - Research Grade

Introduction

Benufutamab Biosimilar is a monoclonal antibody that targets the tumor necrosis factor receptor superfamily member 10B (TNFRSF10B), also known as TRAIL receptor 2 (TRAILR2) or CD262. This antibody is a research grade biosimilar of the anti-TNFRSF10B antibody and has shown promising results in pre-clinical studies for various cancer types.

Structure of Benufutamab Biosimilar

Benufutamab Biosimilar is a fully humanized monoclonal antibody, meaning it is derived from human cells and has a high affinity for its target. It is composed of two heavy chains and two light chains, each containing a variable region that specifically binds to TNFRSF10B. The antibody has a molecular weight of approximately 150 kDa and is produced using recombinant DNA technology.

Activity of Benufutamab Biosimilar

The main activity of Benufutamab Biosimilar is to bind to TNFRSF10B and block its interaction with the ligand TNF-related apoptosis-inducing ligand (TRAIL). This interaction between TNFRSF10B and TRAIL is crucial for the activation of apoptosis, or programmed cell death, in cancer cells. By blocking this interaction, Benufutamab Biosimilar prevents the growth and survival of cancer cells, leading to their death.

In addition to its direct anti-tumor activity, Benufutamab Biosimilar also has immune-modulating effects. It has been shown to activate natural killer (NK) cells, which are important for the body’s immune response against cancer cells. This activation of NK cells further enhances the anti-tumor activity of Benufutamab Biosimilar.

Application of Benufutamab Biosimilar

Benufutamab Biosimilar has shown promising results in pre-clinical studies for various cancer types, including breast, lung, and colon cancer. It has also shown potential in combination with other anti- cancer therapies, such as chemotherapy and radiation therapy.

The potential of Benufutamab Biosimilar as a therapeutic agent is further supported by its favorable safety profile in pre-clinical studies. It has shown minimal toxicity and no significant side effects, making it a promising candidate for further development as a cancer treatment.

Future Directions

Currently, Benufutamab Biosimilar is in the pre-clinical stage of development. However, with its promising results and potential as a therapeutic agent, further studies are needed to evaluate its efficacy and safety in clinical trials. If successful, Benufutamab Biosimilar could potentially become a valuable addition to the existing anti- cancer therapies.

Conclusion

Benufutamab Biosimilar is a research grade monoclonal antibody that targets TNFRSF10B, a key player in the apoptosis pathway. It has shown promising results in pre-clinical studies for various cancer types and has a favorable safety profile. Further studies are needed to evaluate its potential as a therapeutic agent in clinical trials. With its unique mechanism of action and potential for combination therapy, Benufutamab Biosimilar has the potential to become a valuable addition to the existing anti- cancer treatments.